Mild to Moderate Alzheimer's Disease Clinical Trial
Official title:
Safety, Tolerability and Pharmacokinetics of 3 Dose Regimens of AZD1446 vs. Placebo as an Add-on Treatment to Donepezil: A Multi-centre, Double-blind, Randomised, Placebo Controlled, Parallel Group Phase IIa Study in Patients With Mild to Moderate Alzheimer's Disease During 4 Weeks of Treatment
The primary purpose of the study is to determine the safety and tolerability of AZD1446 vs Placebo given as an add-on treatment to Donepezil for 4 weeks in patients with mild to moderate Alzheimer's disease.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT05189210 -
GV1001 Subcutaneous(SC) for the Treatment of Mild to Moderate Alzheimer's Disease (AD)
|
Phase 2 | |
| Active, not recruiting |
NCT03507790 -
A Study to Evaluate the Safety and Efficacy of CT1812 in Subjects With Mild to Moderate Alzheimer's Disease.
|
Phase 2 | |
| Completed |
NCT02703636 -
NextStep:Study to Evaluate Safety,Efficacy & Tolerability of Rivastigmine Patch in Mild to Moderate Alzheimer's Patients.
|
Phase 4 | |
| Completed |
NCT03867253 -
Testing the Safety and Preliminary Efficacy of the New Drug ORY-2001 in Mild to Moderate Alzheimer's Disease
|
Phase 2 | |
| Enrolling by invitation |
NCT06008639 -
Efficacy and Safety of Near Infrared Light Therapy for Alzheimer's Disease
|
N/A | |
| Completed |
NCT03069014 -
Study of LM11A-31-BHS in Mild-moderate AD Patients
|
Phase 1/Phase 2 | |
| Completed |
NCT03625622 -
Efficacy and Safety of 26-Week Treatment of AR1001 in Patients With Mild to Moderate Alzheimer's Disease
|
Phase 2 |